

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, February 1, 2013 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, hereinafter called the “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Reasons for the acquisition of own shares
To improve capital efficiency and shareholder return.

 2. Contents of acquisition
 - (1) Class of shares to be acquired: Common stock of the Company
 - (2) Total number of shares to be acquired: Up to 6 million shares
(The percentage compared to the total number of shares outstanding: 1.31%)
 - (3) Aggregate amount of acquisition cost: Up to 30 billion yen
 - (4) Period of acquisition: From February 4, 2013 to March 18, 2013
- (Reference)
The status of treasury stock as of December 31, 2012:
Total number of shares outstanding: 457,144,547 shares
Number of treasury stock: 10,820,088 shares

#####

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX: +81-3-5201-7473 http://www.astellas.com/en